The three-component nanoparticle of this investigation consisted of an anti-type I regulatory subunit a of the cyclic AMP-dependent protein kinase A (RIa) antisense phosphorodiamidate morpholino (MORF) oligomer, a tat peptide and the anti-HER2 Herceptin antibody each biotinylated and each linked via streptavidin and tested in SUM190 (HER2 þ ), SUM149 (HER2À) and SK-BR-3 (HER2 þ ) cells in culture, using both radioactivity and fluorescent labels on the antisense and control sense MORF. Within the nanoparticle, the antibody provides specific binding to the target cells, the tat improves cellular delivery and the MORF provides the specific retention of the radioactivity in the target cell nucleus. The results show that within the nanoparticle, the Herceptin was still able to bind to its determinant; that the MORF escaped entrapment with its mRNA-binding ability preserved and that the tat maintained its carrier function. Fluorescence microscopy showed evidence of antisense MORF internalization, separation from Herceptin and migration to the nucleus. In conclusion, streptavidin appears to provide an easy means of mixing and matching components to improve the tumor-specific targeting, cell membrane transport, pharmacokinetics and other properties of antisense and other oligomers. Combining the three components of this investigation with streptavidin apparently did not interfere with the properties of each component in cell culture and significantly improved delivery.
Introduction
The results of recent investigations from these laboratories and elsewhere suggest that DNAs and other oligomers for in vivo antisense (AS) imaging, gene therapy and RNAi targeting of tumor may require carriers for improved transmembrane delivery. Fortunately, a large number of potential carriers have been identified primarily for use in cell culture but with increasing reports of successful in vivo use as well. 1 In part to simplify the preparation of carrier/oligomer constructs by avoiding covalent conjugation, streptavidin has been considered as a linker. 2, 3 We had previously demonstrated that the arginine-rich peptides as carriers with streptavidin as a linker are able to improve the cell membrane transport of radiolabeled AS DNAs and other oligomers in vitro. 4 In that investigation we demonstrated that the addition of streptavidin may not have interfered with the cellular delivery function of the tat and polyarginine carriers in vitro in these two-component nanoparticles. Subsequent studies in xenografted mice are showing favorable pharmacokinetics without rapid accumulation in normal tissues such as liver. 5 However, despite favorable pharmacokinetics and unimpeded properties of the AS DNA and its carriers, no important improvement in tumor accumulation of the radiolabeled AS DNA was observed.
In this investigation, we report on the first cell culture studies of a three-component nanoparticle in which the Herceptin anti-HER2 antibody has been added to the nanoparticle with the labeled anti-type I regulatory subunit a (RIa) phosphorodiamidate morpholino (MORF) oligomer and the tat peptide. The addition of an antitumor antibody is expected to improve the target/ nontarget radioactivity ratios by providing tumor-specific targeting when the nanoparticles are next used in vivo. The addition illustrates several of the advantages to the use of streptavidin, namely, the simplicity of the nanoparticle preparation and the ease with which different nanoparticles may be constructed and tested.
The HER2 transmembrane receptor is overexpressed in 25-30% of human breast cancer and is associated with a more aggressive tumor phenotype, poor prognosis and faster relapse times at all stages of cancer development. 6, 7 As a target antigen, HER2 is a readily accessible cell surface receptor and provides a basis for selective immunotargeting of tumor cells. Herceptin (Trastuzumab), a humanized monoclonal antibody against the extracellular domain of HER2, is approved for the adjuvant treatment of patients with HER2-positive metastatic breast cancer. Tat-streptavidin has been used to deliver large biotinylated cargoes to intracellular compartments. 8, 9 We report herein on a modification of our twocomponent nanoparticle that is showing promising results in vitro and in vivo into a three-component nanoparticle by the addition of a tumor-directing antibody to provide tumor-targeting properties in addition to the cell membrane transport and AS-binding properties.
Materials and methods

Chemicals and cell lines
The 15-mer AS MORF (5 0 -GCGTGCCTCCTCACTG GC) directed against the RIa mRNA (GenBank accession number: NM_002734) and the sense (S) control MORF (5 0 -GCCAGTGAGGAGGCACGC) were obtained with a biotin group on the 3 0 equivalent end via a 6-aminohexanoic acid linker and a primary amine on the opposite end (GeneTools, Philomath, OR). The S-acetyl NHS-MAG3 was synthesized in house 10 and its structure confirmed by elemental analysis, proton nuclear magnetic resonance and mass spectroscopy. The tat (biotin-G-R-K-K-R-R-Q-R-R-R) was purchased high-performance liquid chromatography (HPLC) purified as the native L isomer with the biotin attached to the amine end via a 6-aminohexanoic acid linker (21st Century Biochemicals, Marlboro, MA). The Herceptin (Trastuzumab) was obtained from Genentech Inc. (South San Francisco, CA). The biotinylation reagent Sulfo-NHS-LC-Biotin was purchased from Pierce (Rockford, IL) and used to biointylate the Herceptin antibody. Streptavidin was purchased from Sigma (St Louis, MO). Standard chemicals were obtained from various suppliers and used without purification. The Tc99m pertechnetate was eluted from a Mo99-Tc99m generator (Bristol-Myers Squibb Medical Imaging Inc., North Billerica, MA).
The human breast cancer cell lines SUM190 and SUM149 were purchased from Asterand Company (Detroit, MI) and the SK-BR-3 cell line from ATCC (Manassas, VA). The SUM190 cells were grown in Ham's F-12 medium with 2% fetal bovine serum (FBS), and maintained in F-12 without the FBS. The SUM149 cells were cultured and maintained in the Ham's F-12 medium with 5% FBS. The SK-BR-3 cells were cultured and maintained in the McCoy's 5a medium with 10% FBS. The HER2 expression of all three cell lines was evaluated by fluorescence-activated cell sorting (FACS) analysis and the RIa mRNA expression of these cells was confirmed by reverse transcription RT-PCR.
Oligomer conjugation and radiolabeling All oligomers were conjugated with S-acetyl NHS-MAG3 via the derivatized amine and radiolabeled as previously described. 4 In this study, the MORFs were radiolabeled before addition to the nanoparticle since elevated temperatures and/or alkaline pH is required to achieve high radiochemical purity with the MAG3 chelator, conditions that would have denatured the Herceptin antibody. Alternatively, the MORFs could have been radiolabeled after the addition to the nanoparticle and at room temperature and neutral pH, but this would have provided lower radiochemical purity and would have necessitated postlabeling purification. 10 The MORF oligomers were conjugated with the Cy3 fluorophore as follows: The Cy3-NHS (GE Healthcare, Piscataway, NJ) was dissolved in anhydrous N-methyl-2-pyrrolidinone (NMP) at a concentration of 25 mg ml
À1
. About 400 mg of each MORF oligomer dissolved in 80 ml of 0.30 M 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid (pH 8.03) and 25 ml of Cy3-NHS in anhydrous NMP (molar ratio Cy3-NHS to oligomer 17.8:1) was added to this solution. The mixture was vortexed thoroughly and incubated in the dark at room temperature for 1 h before purification on a P4 column using 0.25 M ammonium acetate as eluant. Two pink-colored bands were observed due to free and conjugated Cy3. The latter was collected and concentrated on a Savant Speed Vac (Cambridge Scientific Products, Cambridge, MA) and the concentration determined by measuring absorbance at 265 nm. The average number of Cy3 group per MORF oligomer molecule was determined according to the manufacturer's instruction.
Biotinylation of Herceptin antibody
The Herceptin antibody was biotinylated according to the procedure reported previously. 11 Briefly, 5 mg of Herceptin from a reconstituted commercial vial was purified from histidine by dialyzing against 0.1 M NaH-CO 3 solution, pH 8.5 overnight. After dialysis, 0.12 mg of epsino-caproylamido-biotin-N-hydroxysuccinimide ester (Pierce) was added. The preparation was mixed by gentle agitation for 4 h at room temperature and then dialyzed again against phosphate-buffered saline (PBS) overnight. The product was stored at 4 1C.
Nanoparticle preparation and testing
The streptavidin/tat was first prepared by adding very slowly and with vigorous agitation 11.6 ml of tat at 0.5 mg ml À1 to 20 ml of streptavidin at 10.0 mg ml À1 (molar ratio 1:1), both dissolved in 0.5 M NaCl and 0.2 M ammonium acetate. Although the addition was equimolar, the formation of significant concentrations of the higher order streptavidin/tat nanoparticles is still possible. That the product was free of higher order tat nanoparticles, that is, two to four tat peptides per nanoparticle, was confirmed by adding tracer levels of Tc99m-labeled biotinylated tat peptide to the tat solution before the addition to streptavidin and analyzing the product by size exclusion HPLC with in-line UV and radioactivity detection using 20% acetonitrile in 1 M NaCl, 0.1 M ammonium acetate as eluant at a flow rate 0.6 ml min
À1
. The appearance of a single peak in the UV trace at 280 nm corresponding to a single peak in the radioactivity trace was evidence of both complete complexation and absence of higher order products since this assay is capable of resolving 1:2 and higher order nanoparticles. 4 In the subsequent addition of MORF to the streptavidin/tat nanoparticle, the absence of higher order MORF/tat nanoparticles was established in the same manner by adding tracer levels of Tc99m-labeled biotinylated MORF to the MORF before the addition to streptavidin and followed by HPLC analysis. Finally, the biotinylated Herceptin was added in the same manner but with gentle agitation to avoid denaturing the antibody. In this case, the complete complexation of biotinylated Herceptin to the MORF/tat/streptavidin nanoparticle was confirmed by agarose gel electrophoresis. The MORF and Herceptin two-component nanoparticle was prepared in the identical fashion and was used only for the gel electrophoresis study stability.
RT-PCR
Both SUM cells and the SK-BR-3 cells were examined for RIa mRNA expression relative to b-actin by RT-PCR as previously described to confirm levels sufficient for this investigation. 12 Flow cytometry analysis of HER2 expression Both SUM cells were suspended in ice-cold 3% bovine serum albumin (BSA)/PBS at about 10 7 cells per ml. The flow cytometry studies were performed by adding 2 mg ml À1 of an equal mixture of biotinylated Herceptin and native Herceptin followed by incubation for 1 h at room temperature. The cells were then washed three times with PBS and incubated with fluorescein isothiocyanate (FITC)-labeled anti-human immunoglobulin G (IgG) antibody (Sigma) and anti-biotin IgG antibody (Sigma) in ice-cold 3% BSA/PBS for 30 min at room temperature in the dark. After washing again with PBS, the cells were resuspended in ice-cold PBS and analyzed on a Becton Dickinson flow cytometer (BD Biosciences, Franklin Lakes, NJ) using CellQuest software (BD Biosciences).
Gel electrophoresis
Using nonradiolabeled AS MORF, the MORF onecomponent nanoparticle, the MORF and tat and the MORF and Herceptin two-component nanoparticles and the MORF, tat and Herceptin three-component nanoparticle were incubated in 37 1C PBS or 60% normal mouse serum (Jackson ImmunoResearch Lab Inc., West Grove, PA), in all cases at a final MORF concentration of 10 nM, and samples removed at 1 and 24 h. The complementary phosphodiester DNA was added to each sample before analysis to form the charged duplex, and the samples were developed by gel electrophoresis on a 0.7% agarose gel containing 0.02% ethidium bromide and photographed using Kodak Imaging Station 440 CF (Kodak, New Haven, CT).
Cellular accumulation studies
The cells were plated in 24-well plates and were incubated for 0, 1, 3, 5 or 7 h with the Tc99m-labeled AS and S MORFs as the one, two or three-component nanoparticle in FBS-free (SUM190) or 0.5% FBS (SUM149) Ham's F-12 medium. At harvest, the radioactive medium was aspirated out, each well was rinsed with 1 ml PBS and the cells were then lysed with 1 ml of 0.2 M NaOH containing 1% SDS to ensure complete recovery of radioactivity. The contents of the wells were collected into additional counting tubes along with 1 ml of rinse. The tubes were counted in an automatic NaI (TI) well counter along with a counting standard.
Fluorescence microscopy
Because of the low intensity of the Cy3 fluorophore in these cell studies, it was necessary to use the Texas Red-labeled anti-Cy3 antibody as probe to establish the cellular distribution of the MORF.
The intracellular distribution of Cy3-labeled AS MORF/tat/Herceptin nanoparticles was measured in SK-BR-3 cells seeded onto eight-well chambered coverglass (Nalge Nunc Inc., Rochester, NY) and incubated in 10% FBS/Dulbecco's Modified Eagle Medium overnight. Because of difficulties in preparing monolayers with the SUM190 cells, SK-BR-3 cells were used for this measurement. The cells were divided roughly in half, and half were incubated in serum-free medium with nanoparticles at 50 nM for 2 h and then with FITC-labeled transferrin at 20 mg ml À1 (Molecular Probes, Eugene, OR) for 1 h, always at 37 1C. Thereafter the cells were washed with PBS twice, and were fixed in 3% paraformaldehyde, 0.02% glutaraldehyde in PBS for 15 min at room temperature before being placed at À20 1C in methanol for 10 s. The cells were then washed three times with PBS and were incubated with Texas Red-labeled anti-Cy3 antibody (Abcam, Cambridge, MA), diluted 1:200, for 1 h at room temperature in the dark. Finally, the cells were washed three times with 1% BSA/PBS.
The remaining half of the SK-BR-3 cells was incubated with nanoparticles in the identical fashion as above but without the labeled transferrin. Instead, the cells were incubated after fixation with Texas Red-labeled antiCyanine antibody as before but now along with the FITC-labeled anti-human IgG antibody at 2 mg ml À1 again for 1 h at room temperature in the dark.
Prior to microscopy and photography, all cells were also incubated with 4-6-diamidino-2-phenylindole DAPI (Molecular Probes) at 100 nM in PBS for 5 min at room temperature for nuclear staining.
Statistical analysis
The cell accumulation data are presented as the mean±s.d. of at least N ¼ 3 and statistical analysis was performed using Student's t-test. A P-value o0.05 was considered statistically significant.
Results
RT-PCR
The results of RIa mRNA expression obtained by RT-PCR and electrophoresis with ethidium bromide staining are presented in Figure 1 . The figure shows that the RIa mRNA expression in all three cell lines is relatively high and comparable to that of the internal reference b-actin mRNA expression and therefore suitable for this investigation.
Flow cytometry analysis of HER2 expression
The histograms of Figure 2 presents the percent accumulation in the SUM190 vs SUM149 cells by FACS analysis using FITC-labeled anti-human and anti-biotin IgG antibodies as probes. The high percent accumulation of both probes in SUM190 (HER2 þ ) cells compared to SUM149 (HER2À) cells confirms the relative HER2 epitope activity of each cell type. In addition, that the biotinylated and native Herceptin antibodies accumulated equally in the SUM190 cells as shown by the identical accumulations of the anti-human antibody probe is evidence that the epitope-binding activity of the biotinmodified Herceptin was unaltered from that of the native Herceptin.
Gel electrophoresis
Gel electrophoresis with ethidium bromide detection was used to evaluate the stability of the MORF and Herceptin within the nanoparticle in PBS and in 60% normal mouse serum. Because MORF oligomers are uncharged, it was necessary to form the duplex with the complementary phosphodiester DNA before electrophoresis. As shown in Figure 3 and as expected, the MORF and the MORF/tat nanoparticles migrate ahead of the MORF/Herceptin and the MORF/tat/Herceptin nanoparticles because of the added molecular weight of the Herceptin. Under the conditions of this electrophoresis, free MORF resulting from nanoparticle dissociation will migrate as the phosphodiester DNA duplex ahead of any Herceptin nanoparticle to a position approximately equal to that of the MORF and MORF/tat nanoparticles (the MORF and the MORF/tat nanoparticles were not separated at the gel concentration used in this assay). Accordingly, any instability separating the MORF and Herceptin within the nanoparticle will be apparent. Figure 3 shows essentially the identical trace for all samples whether incubated in 37 1C PBS or in 60% serum for 1 or for 24 h Fluorescence microscopy Fluorescence microscopy was performed in SK-BR-3 cells to visualize the internalization and intracellular localization using Texas Red-labeled anti-Cy3 antibody as a Cy3-AS MORF marker, FITC-labeled transferrin as an internalization maker, FITC-labeled anti-human IgG as a Herceptin marker and DAPI as a nuclear marker. The SK-BR-3 cells have similar expression levels of HER2 (data not shown) and RIa mRNA as the SUM190 cells (Figure 1 ), but grow in monolayers suitable for microscopy. As shown in Figure 5 (panel a), the anti-Cy3 antibody MORF marker (red stain) and the transferrin internalization marker (green stain) are co-localized (shown in yellow) within the cell. This result provides evidence that the MORF has internalized after a 2 h incubation. Also as shown in the figure (panel b) , the MORF marker (red stain) and the anti-human IgG Herceptin marker (green stain) are not co-localized, with the Heceptin predominantly on the cell surface and in the cytoplasm, and the MORF appearing within the cell and predominantly co-localized with DAPI (blue stain) in the nucleus. This result provides evidence that after a 2 h incubation, the MORF has largely dissociated from the Herceptin (and possibly the nanoparticle as well) and migrated to the nucleus.
Discussion
Whether for antisense imaging, gene therapy or RNAi applications, delivery remains the biggest problem to the in vivo use of oligomers. The radiolabeled DNAs and their analogues such as MORFs are currently characterized to varying degree by the same limitation: poor pharmacokinetic delivery to the target following intravenous administration and, in the case of applications with intracellular targets, poor delivery through cell membranes. 1, 13 Attempts to increase delivery are now often focused on the use of oligomer/carrier constructs in which the carrier is intended to improve pharmacokinetics, for example, by adding an antitumor antibody to direct the construct to its target, or more commonly, adding a carrier intended to improve cellular accumulations by chaperoning the oligomer through cellular membranes primarily in vitro but increasingly now in vivo as well.
This laboratory is developing a two-component delivery nanoparticle in which the radiolabeled MORF is attached to a transfecting peptide such as tat via streptavidin as a linker and that may improve the accumulation of AS oligomers in tumor tissue. 5 However, the results of investigations with this nanoparticle have convinced us that it may be useful to also add tumorspecific targeting to the nanoparticle. Free antitumor antibodies have been successfully used to target tumor antigens for decades 14 and are now in increasing use to bring quantum dots and other large particles to tumors. [15] [16] [17] We report herein on our first results using a three-component nanoparticle to which an antitumor antibody has been added to the two-component nanoparticle with the AS MORF and the tat peptide. As before, each component was biotinylated so that streptavidin could serve as a convenient linker.
Serum stability studies presented in Figure 3 show that the MORF oligomers remained associated with the Herceptin nanoparticles at least over 24 h at 37 1C in PBS and in 60% normal mouse serum. The cellular accumulation studies presented in Figure 4 show that the Herceptin within the nanoparticle was able to bind to its determinant, that the MORF within the nanoparticles may have escaped entrapment with preserved mRNAbinding ability and that the tat within the nanoparticle still exhibited its carrier function. Whether these functions were compromised to a modest degree by binding to streptavidin was not established in this research.
The results of fluorescence microscopy are presented in Figure 5 . As shown, the MORF/tat/Herceptin nanoparticle was internalized within 2 h of incubation with the Cy3-AS MORF appearing in the nucleus. Thus the AS MORF certainly dissociated from Herceptin and may also have dissociated from the nanoparticles as well prior to its migration to the nucleus presumably to bind to its mRNA target therein.
In a parallel investigation, this laboratory has determined that the streptavidin nanoparticle is capable of carrying its AS oligomer into cells in culture followed by decreased cellular expression of the protein coded for by the target mRNA (Liu, in preparation) . For convenience, the study was performed using our usual anti-mdr1 AS DNAs and MORFs administered to KB-G2 (Pgp þ þ ) and KB-31 (Pgp þ /À) cells in culture and using Rhodamine 123 accumulation as a measure of Pgp expression. The results show significantly higher accumulations of Rhodamine 123 fluorescence in the study KB-G2 cells but not in the control KB-31 cells when incubated with the nanoparticles.
Chief among the remaining issues concerning the use of the nanoparticle for tumor targeting is pharmacokinetics. Studies with our MORF two-component nanoparticle in normal mice are showing about 4.5% in liver and 10% remaining in blood after 3 h and therefore pharmacokinetics favorable for tumor imaging (Y Wang, unpublished observations, 2007). Presumably, the addition of the antitumor antibody to the nanoparticle will not unfavorably alter this conclusion.
In future studies in tumored animals, the antitumor antibody and the tat within the nanoparticle are expected to provide favorable tumor/nontumor accumulation ratios, while the AS oligomer is expected to increase the retention of radioactivity in tumor, the combination therefore may improve tumor detection. Furthermore, in this as in previous studies, we have shown that AS oligomers accumulate primarily in the nucleus. 18, 19 Accordingly, the three-component nanoparticle may achieve its primary utility in accumulating and retaining short-range Augeremitting radionuclides such as In111 in the nucleus of cancer cells in connection with radiotherapy. 20 In conclusion, the results of this investigation support our earlier observations that attaching biotinylated components using streptavidin as a linker does not appear to interfere with the properties of each component for AS targeting of tumor cells and will be further considered for improved tumor delivery.
